ArticlePediatric research2026
Interindividual variability in metformin pharmacokinetics in pediatric patients.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetformin is the first-line treatment for type 2 diabetes mellitus in pediatric patients and it's prescriptions in children have increased for off-label indications. However, interindividual variability of metformin pharmacokinetics in children is not well studied. Metformin is a cation that requires multiple transporters for its absorption, distribution and elimination, including organic cation transporters (OCTs) and multidrug and toxin extrusion (MATE) transporters.
methodsWe conducted a 12 h clinical pharmacokinetic study in 36 pediatric patients (age, 7-21 years) treated with metformin and analyzed the data using non-compartmental and population pharmacokinetic models to describe metformin pharmacokinetics and associated covariates. The association of OCT and MATE genetic variants on metformin absorption and elimination was investigated.
resultsThe dose-normalized plasma exposure of metformin varied by 3.3-fold among children. Renal clearance was higher in children compared to the reported data in healthy adults or adults with diabetes. Total body weight (TBW) and estimated glomerular filtration rate (eGFR) significantly affected metformin oral clearance. OCT2 c.390 G > T (p.Thr130 = , rs624249) was associated with metformin oral clearance and secretary clearance, whereas OCT3 c.-29G > A (rs555754) and c.360 C > T (p.Arg120 = , rs668871) were significantly associated with the absorption rate constant and oral clearance.
conclusionMetformin dosing in children can be optimized based on TBW, eGFR, and OCT2/3 genetic variants to improve its safety and efficacy. IMPACT: Metformin pharmacokinetics is highly variable, and limited data are available on the pediatric population. Total body weight and estimated glomerular filtration rate are associated with metformin oral clearance. OCT2/3 genetic variants can influence the elimination and absorption of metformin. Consideration of population factors associated with metformin pharmacokinetics in dose selection can improve its safety and efficacy.
Identifiers
42399684What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.